BR 115
Alternative Names: BR-115Latest Information Update: 31 May 2024
At a glance
- Originator BioRay Pharmaceutical; Chengdu Enmu Biotechnology
- Developer BioRay Pharmaceutical
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 29 Apr 2024 BioRay Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in China (SC, Injection) in April 2024 (NCT06388902)
- 19 Jan 2024 Chengdu Enmu Biotechnology has patent protection for TRIAD triple antibody technology
- 19 Jan 2024 Preclinical trials in Solid tumours in China (SC) before January 2024